GenMark Diagnostics Inc. (NASDAQ:GNMK) fell 3% on Monday . The company traded as low as $9.62 and last traded at $9.68, with a volume of 125,535 shares trading hands. The stock had previously closed at $9.98.

A number of brokerages have weighed in on GNMK. Canaccord Genuity reiterated a “buy” rating on shares of GenMark Diagnostics in a research note on Wednesday, June 8th. Needham & Company LLC began coverage on shares of GenMark Diagnostics in a research note on Friday, June 17th. They set a “buy” rating and a $13.00 target price for the company. Two investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The company presently has a consensus rating of “Buy” and an average target price of $8.43.

The stock’s market capitalization is $409.05 million. The firm has a 50-day moving average of $8.45 and a 200 day moving average of $6.43.

GenMark Diagnostics (NASDAQ:GNMK) last announced its earnings results on Tuesday, May 3rd. The company reported ($0.30) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.29) by $0.01. During the same period last year, the business posted ($0.24) EPS. The business had revenue of $11.06 million for the quarter, compared to the consensus estimate of $10.67 million. The firm’s quarterly revenue was up 9.5% compared to the same quarter last year. On average, analysts expect that GenMark Diagnostics Inc. will post ($1.23) earnings per share for the current fiscal year.

A number of large investors have recently made changes to their positions in the stock. Jennison Associates LLC increased its stake in shares of GenMark Diagnostics by 7.3% in the fourth quarter. Jennison Associates LLC now owns 3,144,434 shares of the company’s stock valued at $24,401,000 after buying an additional 214,822 shares during the period. Morgan Stanley increased its stake in shares of GenMark Diagnostics by 10,433.5% in the fourth quarter. Morgan Stanley now owns 1,338,286 shares of the company’s stock valued at $10,385,000 after buying an additional 1,325,581 shares during the period. Casdin Capital LLC purchased a new stake in shares of GenMark Diagnostics during the fourth quarter valued at $2,406,000. Finally, I.G. Investment Management LTD. increased its stake in shares of GenMark Diagnostics by 0.7% in the fourth quarter. I.G. Investment Management LTD. now owns 134,589 shares of the company’s stock valued at $1,044,000 after buying an additional 978 shares during the period.

GenMark Diagnostics, Inc (GenMark) is a molecular diagnostics company. The Company focuses on developing and commercializing its eSensor detection technology. Its eSensor electrochemical technology detects multiple distinct biomarkers in a single sample. It sells its XT-8 instrument and related diagnostic and research tests (XT-8 system) in the United States.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.